Using deep learning, researchers attempted to classify non-small lung cancer subtypes and predict lung adenocarcinoma mutations from histopathology slides.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
